Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

The company says broad tariffs would raise costs, limit patient access and undermine domestic manufacturing. Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would ...

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...

Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe ...